Status:
COMPLETED
Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19)
Lead Sponsor:
University Hospital, Montpellier
Conditions:
COVID-19
Renal Replacement Therapy
Eligibility:
All Genders
18-100 years
Brief Summary
Among patients with SARS-CoV-2 pneumonia, approximately 20% have an acute kidney injury (AKI) and 5% require renal replacement therapy. Occurrence of AKI in patients with COVID-19 is associated with i...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Age ≥ 18 years
- COVID-19 confirmed by positive SARS-CoV-2 PCR
- at least one urine sample
- Exclusion criteria:
- Persons under protection
- Paritcipation rejections
Exclusion
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04393428
Start Date
March 1 2020
End Date
June 30 2020
Last Update
July 29 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uhmontpellier
Montpellier, France, 34295